Role of Hydroxychloroquine in therapeutic strategy of Head and Neck cancer and Nonsmall cell lung cancer

Prior treatment

• Any regular concomitant medication which is contraindicated in the use together with HCQ

Other illness

• Hypersensitivity to Hydroxychloroquine, Chloroquine or other 4-Aminoquinolines4
• Diabetes type 1
• Haematopoietic systems diseases
• Bradycardia or reduction in heart rhythm with arrhythmia
• Congestive heart failure with use of diuretics

Lab values

• Known Glucose-6-phosphate dehydrogenase deficiency (haemolytic anaemia, Favism)
• Known galactose intolerance, total lactase deficiency, or glucose-galactose malabsorption
• Known prolonged QT syndrome or current use of drugs with known prolongation of QT/QTc interval.

Age

• Ischemic heart disease (< 5 years)

Other

• Myasthenia gravis
• Psoriasis
• Pregnant or breastfeeding women
• Patients with Nasogastric or PEG feeding tube
• Patients with deterioration of performance status beyond ECOG 2
• Uncorrected hypokalemia and/or hypomagnesemia
• Pre-existing retinopathy or maculopathy5

• Head and Neck Cancer group: - Adults > or = 18 years of age. - American Joint Committee on Cancer-defined clinical stage I, II, III, IV HN cancer that is deemed locally to be surgically resectable by a multidisciplinary clinical team and will receive radical surgery. - Squamous Cell Carcinoma (SCC) of the oral cavity or larynx - Treatment-naïve patients - Eastern Cooperative Oncology Group (ECOG) performance status 0-2 - Patient capable giving informed consent - QTc interval lower than 450 msec - Measurable or evaluable disease defined by RECIST 1.1 - For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 4 weeks after the end of drug administration. - For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner
• Non-small cell lung cancer group - Adults > or = 18 years of age. - American Joint Committee on Cancer-defined clinical stage IA, IB, IIA, IIB NSCLC that is deemed locally to be surgically resectable by a multidisciplinary clinical team and will receive radical surgery. - Lung Squamous Cell Carcinoma or Adenocarcinoma. - Treatment-naïve patients - PDL1 > 50% - Eastern Cooperative Oncology Group (ECOG) performance status 0-2 - Patient capable giving informed consent - QTc interval lower than 450 msec - Measurable or evaluable disease defined by RECIST 1.1 - For females of reproductive potential: use of highly effective contraception for at least 1 month prior to screening and agreement to use such a method during study participation and for an additional 4 weeks after the end of drug administration. - For males of reproductive potential: use of condoms or other methods to ensure effective contraception with partner